(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three biggest winners today are Cocrystal Pharma, Xenetic Biosciences, and Conifer Holdings.

Rank Financial Asset Price Change Updated (EST)
1 Cocrystal Pharma (COCP) 2.79 19.18% 2023-01-24 15:46:17
2 Xenetic Biosciences (XBIO) 0.53 13.81% 2023-01-24 15:49:46
3 Conifer Holdings (CNFR) 1.90 13.77% 2023-01-24 15:13:07
4 Golden Bull Limited (BTBT) 1.42 12.7% 2023-01-24 07:09:15
5 BigCommerce Holdings (BIGC) 11.96 10.33% 2023-01-23 23:09:19
6 Blink Charging Co. (BLNKW) 9.90 10.24% 2023-01-23 23:47:15
7 Centogene N.V. (CNTG) 1.13 9.71% 2023-01-24 15:23:16
8 Brilliant Acquisition Corporation (BRLIW) 0.05 9.34% 2023-01-24 02:23:16
9 Benitec Biopharma (BNTC) 0.25 9.08% 2023-01-24 01:10:29
10 Catalyst Pharmaceuticals (CPRX) 16.07 8.87% 2023-01-24 15:55:19

The three biggest losers today are Brooge Energy Limited , BioCardia, and Wayfair.

Rank Financial Asset Price Change Updated (EST)
1 Brooge Energy Limited (BROGW) 0.16 -11.11% 2023-01-24 03:07:15
2 BioCardia (BCDAW) 0.80 -9.22% 2023-01-23 21:12:12
3 Wayfair (W) 54.96 -7.37% 2023-01-24 15:51:09
4 Magna International (MGA) 60.85 -7.05% 2023-01-24 15:55:05
5 SmileDirectClub (SDC) 0.54 -6.47% 2023-01-24 15:48:54
6 Brooge Energy Limited (BROG) 5.80 -6.32% 2023-01-24 03:06:08
7 Sorrento Therapeutics (SRNE) 1.01 -6.07% 2023-01-24 15:01:56
8 3M Company (MMM) 115.43 -5.86% 2023-01-24 15:55:16
9 Aspen Group (ASPU) 0.32 -5.75% 2023-01-24 15:03:17
10 Catalent (CTLT) 49.59 -5.7% 2023-01-24 15:52:12

Winners today

1. Cocrystal Pharma (COCP) – 19.18%

Cocrystal Pharma, Inc. is a biotechnology firm that focuses on developing antiviral therapies for severe and/or persistent viral diseases. The company uses structure-based technology to develop antiviral medications mainly to combat hepatitis C virus, influenza virus, coronavirus and norovirus infection. The company is currently developing CC-31244, a non-nucleoside monomerase inhibitor for HCV. It has successfully completed Phase 2a clinical trials to treat HCV infection. CC-42344, a PB2 inhibit that is being developed in preclinical studies to combat influenza. The company is involved in the development of non-nucleoside monomerase inhibitors to treat norovirus infections. Cocrystal Pharma, Inc. holds a research collaboration and license agreement with Merck Sharp & Dohme Corp. for discovery and development of proprietary influenza A/B antiviral substances; a license agreement to Kansas State University Research Foundation in order to develop antiviral compounds to treat norovirus or coronavirus infection; and a drug discovery collaboration partnership with HitGen Inc. and InterX Inc. It is located in Bothell Washington.

NASDAQ ended the session with Cocrystal Pharma rising 19.18% to $2.79 on Tuesday while NASDAQ dropped 0.27% to $11,334.27.

Earnings Per Share

As for profitability, Cocrystal Pharma has a trailing twelve months EPS of $-0.175.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -54.07%.

More news about Cocrystal Pharma.

2. Xenetic Biosciences (XBIO) – 13.81%

Xenetic Biosciences, Inc. is a biopharmaceutical firm that focuses on advancing XCART, a customized chimeric receptor T cell (CART) platform technology designed to target specific patient-specific tumour neoantigens. It is involved in research and development of oncology therapies and biologic drugs. Cell-based therapies that target the B-cell receptor are developed to treat B-cell lymphomas. By partnering with pharmaceutical and biotechnology companies, it is also using PolyXen, their proprietary drug delivery platform. Takeda Pharmaceutical Co. Ltd. and Serum Institute of India Limited have signed collaboration agreements. Xenetic Biosciences, Inc. has its headquarters in Framingham, Massachusetts.

NASDAQ ended the session with Xenetic Biosciences rising 13.81% to $0.53 on Tuesday while NASDAQ slid 0.27% to $11,334.27.

Earnings Per Share

As for profitability, Xenetic Biosciences has a trailing twelve months EPS of $-1.704.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -59.34%.

More news about Xenetic Biosciences.

3. Conifer Holdings (CNFR) – 13.77%

Conifer Holdings, Inc., a holding company for insurance, is involved in the sales of casualty and property insurance products. The company offers personal and specialty insurance coverage. It offers specialty insurance, such as property, general liability and liquor liability, auto, homeowners, and dwelling policies. The company serves owner-operated business owners in these markets. It also provides commercial insurance for artisan contractors, including plumbers, carpenters and electricians. It also provides specialty homeowners insurance products such as dwelling insurance for those who own lower-value homes in Illinois, Indiana and Texas. Conifer Holdings, Inc. sells and markets its products via a network that includes approximately 6,100 agents across 50 US states. Birmingham, Michigan is the headquarters of Conifer Holdings Inc.

NASDAQ ended the session with Conifer Holdings jumping 13.77% to $1.90 on Tuesday while NASDAQ slid 0.27% to $11,334.27.

Earnings per Share

Conifer Holdings’ trailing 12 month EPS is $0.06.

PE Ratio

Conifer Holdings’ trailing 12-month price-to-earnings ratio is 31.67. The purchaser of the shares is therefore investing $31.67 per dollar in annual earnings.

For the 12 trailing months, the company’s return-on-equity, which is a measure of the profitability of a company relative to shareholders’ equity, was negative at -46.65%.

More news about Conifer Holdings.

4. Golden Bull Limited (BTBT) – 12.7%

Bit Digital, Inc. engages in the bitcoin mining business. The company was formerly known as Golden Bull Limited and changed its name to Bit Digital, Inc. in September 2020. The company is headquatered in New York, New York.

NASDAQ ended the session with Golden Bull Limited jumping 12.7% to $1.42 on Tuesday while NASDAQ slid 0.27% to $11,334.27.

Earnings Per Share

As for profitability, Golden Bull Limited has a trailing twelve months EPS of $0.07.

PE Ratio

Golden Bull Limited has a trailing twelve months price to earnings ratio of 20.29. Meaning,
the purchaser of the share is investing $20.29 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -39.41%.

Yearly Top and Bottom Value

Golden Bull Limited’s stock is valued at $1.42 at 16:32 EST, way below its 52-week high of $5.35 and way higher than its 52-week low of $0.53.

Volume

Today’s last reported volume for Golden Bull Limited is 4700180 which is 182.14% above its average volume of 1665900.

Revenue Growth

Year-on-year quarterly revenue growth declined by 12.2%, now sitting on 37.91M for the twelve trailing months.

More news about Golden Bull Limited.

5. BigCommerce Holdings (BIGC) – 10.33%

BigCommerce Holdings, Inc. operates a software-as-a-service platform for small businesses, mid-markets, and large enterprises in the United States. It offers various services to help you launch and scale your ecommerce business, such as store design, web hosting, cart management, ordering, tracking, pre-integrations, check out, order management and checkout. It served approximately 60,000. The company’s platform was available in 155 different industries. BigCommerce Holdings, Inc., was established in 2009 in Austin, Texas.

NASDAQ ended the session with BigCommerce Holdings jumping 10.33% to $11.96 on Tuesday while NASDAQ fell 0.27% to $11,334.27.

Earnings Per Share

As for profitability, BigCommerce Holdings has a trailing twelve months EPS of $-1.47.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -124.78%.

Growth Estimates Quarters

The company’s growth estimates for the current quarter is a negative 11.8% and positive 44.4% for the next.

Sales Growth

BigCommerce Holdings’s sales growth is 13% for the present quarter and 13% for the next.

Annual Top and Bottom Value

At 16:32 EST BigCommerce Holdings’s stock was valued at $11.96. This is way lower than its 52 week high of $34.00, and much higher than its 52-week low $7.74.

More news about BigCommerce Holdings.

6. Blink Charging Co. (BLNKW) – 10.24%

NASDAQ ended the session with Blink Charging Co. jumping 10.24% to $9.90 on Tuesday while NASDAQ fell 0.27% to $11,334.27.

Annual Top and Bottom Value

Blink Charging Co. stock was valued at $9.90 as of 16:32 EST. This is well below the 52-week low $8.96.

More news about Blink Charging Co..

7. Centogene N.V. (CNTG) – 9.71%

Centogene N.V. and its affiliates are focused on rare diseases. They transform real-world genetic and clinical data into actionable information that can be used by patients, doctors, and pharmacist companies around the world. It is developing a rare disease platform. This data repository includes epidemiologic and phenotypic data. These data can be used to enhance methods of identifying rare hereditary disorders and accelerate development of orphan drug. The company offers a variety of services including patient monitoring, target identification, patient recruitment, diagnosis, epidemiological insight, biomarker discovery and targeted discovery. It also provides genetic sequencing services and diagnostics services directly to doctors, hospitals, labs, or other healthcare professionals through distributors. It also provides COVID-19 test solutions including RTPCR and antigen services. The company has a partnership agreement with Shire International GmbH (and Pfizer Inc.); a cooperation agreement with Dr. Bauer Laboratoriums GmbH Rostock, which provides the COVID-19 test business services; and a license arrangement with Fraport AG, to run a COVID-19 diagnostic/testing center at Frankfurt Airport. Twist Bioscience Corporation will also be used to create advanced sequencing tools. Centogene N.V. is an international company that was established in 2006. Its headquarters are in Rostock.

NASDAQ ended the session with Centogene N.V. rising 9.71% to $1.13 on Tuesday, following the last session’s upward trend. NASDAQ dropped 0.27% to $11,334.27, after two sequential sessions in a row of gains, on what was a somewhat down trend trading session today.

Earnings per Share

Centogene N.V.’s trailing 12 months EPS is $-1.592.

For the 12 trailing months, the company’s return-on-equity, which is a measure of the profitability of a company relative to shareholders’ equity, was negative at -91.4%.

Growth Estimates Quarters

The company’s growth estimates for the ongoing quarter and the next is 18.6% and 67.9%, respectively.

Yearly Top and Bottom Value

Centogene N.V.’s stock is valued at $1.13 at 16:32 EST, way under its 52-week high of $5.18 and way higher than its 52-week low of $0.68.

Moving Average

Centogene N.V. is worth more than its moving average 50 days of $0.86, and much less than its moving average 200 days of $1.79.

More news about Centogene N.V..

8. Brilliant Acquisition Corporation (BRLIW) – 9.34%

NASDAQ ended the session with Brilliant Acquisition Corporation jumping 9.34% to $0.05 on Tuesday, after five successive sessions in a row of losses. NASDAQ fell 0.27% to $11,334.27, after two successive sessions in a row of gains, on what was a somewhat down trend exchanging session today.

Yearly Top and Bottom Value

Brilliant Acquisition Corporation’s stock is valued at $0.05 at 16:32 EST, above its 52-week high of $0.05.

More news about Brilliant Acquisition Corporation.

9. Benitec Biopharma (BNTC) – 9.08%

Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy and chronic hepatitis B virus infection. The company was founded in 1995 and is headquartered in Hayward, California.

NASDAQ ended the session with Benitec Biopharma jumping 9.08% to $0.25 on Tuesday, after two consecutive sessions in a row of gains. NASDAQ fell 0.27% to $11,334.27, after two sequential sessions in a row of gains, on what was a somewhat down trend trading session today.

Earnings per Share

Benitec Biopharma’s trailing twelve-month EPS is $-2.172.

For the 12 trailing months, the company’s return-on-equity, which is a measure of the profitability and shareholder equity for a business, was negative at -121.35%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Benitec Biopharma’s EBITDA is -1.27.

Moving Average

Benitec Biopharma’s value is way higher than its 50-day moving average of $0.18 and way under its 200-day moving average of $0.72.

More news about Benitec Biopharma.

10. Catalyst Pharmaceuticals (CPRX) – 8.87%

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical firm at the commercial stage. It focuses its efforts on commercializing treatments for neurological and rare neuromuscular diseases. Firdapse is an amifampridine-phosphate tablet for patients suffering from lambert–eaton syndrome (LEMS); Ruzurgi, for pediatric LEMS patients. Firdapse is also developed by the company to treat MuSK antibody positive myasthenia Gravis and spinal muscular atrophy Type 3. It can also be used to treat hereditary nervepathy with liability for pressure palsies. Endo Ventures Limited and BioMarin Pharmaceutical Inc. have license agreements. Endo Ventures Limited has a collaboration agreement for the commercialization and development of generic Sabril tablets. Catalyst Pharmaceutical Partners, Inc. was the company’s former name. It changed its name in May 2015 to Catalyst Pharmaceuticals, Inc. Catalyst Pharmaceuticals, Inc., was established in 2002. It is located in Coral Gables, Florida.

NASDAQ ended the session with Catalyst Pharmaceuticals jumping 8.87% to $16.07 on Tuesday, following the last session’s downward trend. NASDAQ dropped 0.27% to $11,334.27, after two sequential sessions in a row of gains, on what was a somewhat bearish trend exchanging session today.

Earnings Per Share

As for profitability, Catalyst Pharmaceuticals has a trailing twelve months EPS of $0.71.

PE Ratio

Catalyst Pharmaceuticals has a trailing twelve months price to earnings ratio of 22.63. Meaning,
the purchaser of the share is investing $22.63 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 25.35%.

Moving Average

Catalyst Pharmaceuticals’s worth is below its 50-day moving average of $17.12 and way above its 200-day moving average of $11.88.

Growth Estimates Quarters

For the current quarter, the company expects to grow by 122.2% and 166.7% respectively.

More news about Catalyst Pharmaceuticals.

Losers Today

1. Brooge Energy Limited (BROGW) – -11.11%

NASDAQ ended the session with Brooge Energy Limited falling 11.11% to $0.16 on Tuesday, after five sequential sessions in a row of losses. NASDAQ slid 0.27% to $11,334.27, after two successive sessions in a row of gains, on what was a somewhat down trend exchanging session today.

Annual Top and Bottom Value

Brooge Energy Limited’s stock was valued at $0.16 as of 16:32 EST. This is way lower than its 52-week low at $0.18.

More news about Brooge Energy Limited .

2. BioCardia (BCDAW) – -9.22%

NASDAQ ended the session with BioCardia sliding 9.22% to $0.80 on Tuesday, after five sequential sessions in a row of losses. NASDAQ slid 0.27% to $11,334.27, after two successive sessions in a row of gains, on what was a somewhat down trend exchanging session today.

Annual Top and Bottom Value

BioCardia stock was valued at $0.80, 16:32 EST. This is below its 52 week high of $0.82 but much higher than its low 52-week of $0.66.

More news about BioCardia.

3. Wayfair (W) – -7.37%

Wayfair Inc. engages in the e-commerce business in the United States and internationally. The company provides approximately thirty-three million products for the home sector under various brands. It offers online selections of furniture, décor, housewares, and home improvement products through its sites, including Wayfair, Joss & Main, AllModern, Birch Lane, and Perigold brands. The company was founded in 2002 and is headquartered in Boston, Massachusetts.

NYSE ended the session with Wayfair sliding 7.37% to $54.96 on Tuesday, after four sequential sessions in a row of gains. NYSE slid 0.11% to $15,862.29, after two successive sessions in a row of gains, on what was a somewhat bearish trend exchanging session today.

Earnings per Share

Wayfair’s trailing 12 months profit per share (EPS) is $1.86

PE Ratio

Wayfair’s trailing 12-month price-to-earnings ratio is 29.55. This means that the buyer of shares is paying $29.55 per dollar in annual earnings.

Revenue growth

The year-on-year revenue growth fell by 13.9%. We now have 13.22B in the 12 trailing months.

Yearly Top and Bottom Value

Wayfair’s stock is valued at $54.96 at 16:32 EST, way under its 52-week high of $298.00 and way above its 52-week low of $36.67.

Volatility

Wayfair’s last week, last month’s, and last quarter’s current intraday variation average was a negative 2.66%, a positive 1.03%, and a positive 4.93%.

Wayfair’s highest amplitude of average volatility was 2.66% (last week), 3.74% (last month), and 4.93% (last quarter).

Previous days news about Wayfair

  • Wayfair stock is rallying today: what's going on?. According to Business Insider on Monday, 23 January, "On Friday, Wayfair announced a 10% workforce reduction, including 18% of corporate employees. ", "W Price Action: Wayfair has a 52-week high of $163.99 and a 52-week low of $28.11."

More news about Wayfair.

4. Magna International (MGA) – -7.05%

Magna International Inc. designs, engineers, and manufactures components, assemblies, systems, subsystems, and modules for original equipment manufacturers of vehicles and light trucks worldwide. It operates through four segments: Body Exteriors & Structures, Power & Vision, Seating Systems, and Complete Vehicles. The Body Exteriors & Structures segment provides body and chassis, exterior, and roof systems, as well as battery enclosures and engineering and testing services, including fascia and trims, front end modules, front integration panels, liftgate modules, active aerodynamics, engineered glass, running boards, truck bed access products, and side doors. The Power & Vision segment offers hybrid and electric drive systems, motors, inverters, onboard chargers, and e-clutch; dedicated hybrid, dual and hybrid dual, and manual transmissions; AWD/4WD products and rear drive modules; transmission, engine, driveline components, engine drive plates, and accessories; engineering services; advanced driver assistance systems and sensors, and electronic control units; interior and exterior mirrors, camera and driver monitoring systems and electronics, actuators, door handles, and overhead consoles; forward, rear, and auxiliary lighting products; latching, door modules, window, power closure, and hinges and wire forming systems; and modular and textile folding roofs, and hard and soft tops. The Seating Systems segment provides seat structures, mechanism and hardware solutions, and foam and trim products. The Complete Vehicles segment offers vehicle engineering and manufacturing services. The company also designs, engineers, and manufactures tooling products. Magna International Inc. was founded in 1957 and is headquartered in Aurora, Canada.

NYSE ended the session with Magna International sliding 7.05% to $60.85 on Tuesday, after four successive sessions in a row of gains. NYSE dropped 0.11% to $15,862.29, after two successive sessions in a row of gains, on what was a somewhat negative trend trading session today.

Earnings per Share

Magna International’s trailing twelve-month EPS is $2.52.

PE Ratio

Magna International’s trailing 12 months earnings to price ratio is 24.14. The purchaser of the shares is therefore investing $24.14 per dollar in annual earnings.

For the 12 trailing months, the company’s return-on-equity, which is an indicator of the business’ profitability relative to shareholders’ equity, was 6.13%.

More news about Magna International.

5. SmileDirectClub (SDC) – -6.47%

SmileDirectClub, Inc., a dental care company, provides clear aligner therapy. It manages all aspects of the treatment process including marketing, manufacturing and fulfillment. The company also monitors patients through their progress through treatment. SmileCheck, Inc. has approximately 250 dentists in America, Canada, Australia and New Zealand. The company also sells aligners and impression and whitening kit, whitening gels and retainers. It also stocks toothbrushes and toothpastes as well as water flossers and SmileSpa and other ancillary products. It was established in Nashville, Tennessee in 2014.

NASDAQ ended the session with SmileDirectClub dropping 6.47% to $0.54 on Tuesday while NASDAQ dropped 0.27% to $11,334.27.

Earnings per Share

SmileDirectClub’s trailing 12 months profit per share is $-2.334

Moving Average

SmileDirectClub is worth more than its moving average for 50 days of $0.53, and far less than its moving average for 200 days of $1.10.

Volatility

SmileDirectClub’s intraday variation average for the week and quarter ended last week at a negative 11.47, a positive 2.94, and positive 7.48%.

SmileDirectClub had the highest average volatility amplitudes of 11.47%, 11.38% and 7.48% in last quarter.

Growth Estimates Quarters

The company’s growth estimates for the current quarter and the next is 8.7% and 12%, respectively.

More news about SmileDirectClub.

6. Brooge Energy Limited (BROG) – -6.32%

Brooge Energy Limited provides related services and oil storage at the Port of Fujairah, in the United Arab Emirates, via its subsidiaries. It operates a phase I facility, which consists of 14 storage tanks that have an aggregate geometrical capacity of 399.324 cm. This is used for storage, heating and blending fuel oil and other petroleum products such as aviation fuel, fuel, gasoline, oil oil, oil oil, oil oil, oil oil, oil oil, oil oil, oil oil, oil oil, oil oil, oil oil, oil of marine, oil and naphtha. The company also offers ancillary services such as blending, circulation, heating and throughput. The original name of the company was Brooge Holdings Limited. In April 2020, it changed its name from Brooge Energy Limited to Brooge Energy Limited. Brooge Energy Limited has its headquarters in Fujairah (the United Arab Emirates).

NASDAQ ended the session with Brooge Energy Limited dropping 6.32% to $5.80 on Tuesday while NASDAQ slid 0.27% to $11,334.27.

Earnings per Share

Brooge Energy Limited’s trailing twelve-month EPS is $0.13.

PE Ratio

Brooge Energy Limited’s trailing 12 months earnings to price ratio is 44.61 The purchaser of the shares is therefore investing $44.61 per dollar in annual earnings.

For the 12 trailing months, the company’s return-on-equity, which is a measure of the profitability and shareholder equity for a company, was 9.1%.

More news about Brooge Energy Limited .

7. Sorrento Therapeutics (SRNE) – -6.07%

Sorrento Therapeutics, Inc. is a commercial and clinical biopharmaceutical firm that develops treatments for neurodegenerative, autoimmune, inflammatory, and cancer. The company operates in two segments: Sorrento Therapeutics, and Scilex. It offers cancer therapy by using its G-MAB antigen library and targeted delivery methods. These include antibody drug conjugate and chimeric antigen- receptor T cell therapy (CAR–T) and bispecific antibody approach. Sofusa is a drug delivery system that delivers biologics directly to the lymphatic systems. The company’s current clinical programs include anti-CD38 CAR–T therapy to treat multiple myeloma and amyloidosis. It produces resiniferatoxin (a non-opioid TRPV1 antagonist neurotoxin) for treatment of late-stage cancers and osteoarthritis. ZTlido is a system that delivers lidocaine for postherpetic neuralgia. SEMDEXA is an injectable viscous jelly formulation that has been developed for treatment of sciatica. SP-103, an investigational topical lidocaine system, is currently in clinical development for chronic low back pain. SP-104, a low-dose, delayed-release formulation of naltrexone hydrochloride for the treatment fibromyalgia. SmartPharm Therapeutics Inc. has collaborated with it to create a gene-encoded vaccine against COVID-19. Celularity, Inc. is responsible for initiating the Phase I/II clinical trial, which included up to 94 patients suffering from COVID-19. Mount Sinai Health System will develop COVID-SHIELD, an anti-SARS treatment. Mayo Clinic was involved in Phase Ib pilot studies using sofusa lymphatic drug transport technology to deliver Ipilimumab to delivery to administer Ipilimuma to give Ipilimuma to Ipilimuma to Ipilimumab to deliver Ipilimuma to Ipilimuma to Ipilimuma to Ipilimuma to deliver Ipilimumab to deliver Ipi to Ipilimuma to Ipilimuma to patient with mela to use to to provide for mela to Ipa to help to take to to give to Mayo It was established in San Diego in 2006.

NASDAQ ended the session with Sorrento Therapeutics falling 6.07% to $1.01 on Tuesday while NASDAQ dropped 0.27% to $11,334.27.

Earnings Per Share

As for profitability, Sorrento Therapeutics has a trailing twelve months EPS of $-1.3.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -326.72%.

Classification of Stock Prices

The stochastic oscillator is a helpful indicator for overbought or oversold situations.

Stock of Sorrento Therapeutics is overbought (>=80).

Volatility

Sorrento Therapeutics’s last week, last month’s, and last quarter’s current intraday variation average was a negative 2.07%, a positive 1.64%, and a positive 5.25%.

Sorrento Therapeutics’s highest amplitude of average volatility was 3.37% (last week), 6.05% (last month), and 5.25% (last quarter).

More news about Sorrento Therapeutics.

8. 3M Company (MMM) – -5.86%

3M Company is a global technology company that offers diversified services. The company operates in four areas: Safety and Industrial, Transportation and Electronics, Health Care and Consumer. Safety and Industrial offers industrial abrasives and metalworking solutions, as well as closures systems for personal hygiene, masking and packaging. It also provides electrical products and materials to support construction and maintenance. This segment includes electrical tapes, structural adhesives and tapes, and natural and colored mineral granules that can be used for roofing. Transportation and Electronics offers ceramic solutions, attachment tapes and films, sound and temperature management for transport vehicles, premium large format graphics films for advertising and fleet signs, light management films and electronic assembly solutions, packaging and interconnection options, and reflective signage to ensure highway safety and vehicle safety. The Healthcare segment provides solutions for food safety, health procedure coding, reimbursement software, skin, wound care and infected prevention products and services, as well as dental and orthodontic solutions. The Consumer segment offers consumer products such as consumer masks, consumer braces and supports, consumer respirators, cleaning products and products for home, retail abrasives and paint accessories, DIY car care products, picture hanging and consumer air quality products. The company sells its products via e-commerce, traditional wholesalers and retailers as well as jobbers and distributors. It was established in St. Paul in Minnesota in 1902.

NYSE ended the session with 3M Company dropping 5.86% to $115.43 on Tuesday, after four sequential sessions in a row of gains. NYSE dropped 0.11% to $15,862.29, after two consecutive sessions in a row of gains, on what was a somewhat negative trend exchanging session today.

Earnings Per Share

As for profitability, 3M Company has a trailing twelve months EPS of $9.77.

PE Ratio

3M Company has a trailing twelve months price to earnings ratio of 11.81. Meaning,
the purchaser of the share is investing $11.81 for every dollar of annual earnings.

Growth Estimates Quarters

For the current quarter, the company expects 6.1% growth and 3.8% drop for the next.

Volatility

3M Company’s last week, last month’s, and last quarter’s current intraday variation average was a negative 2.91%, a negative 0.01%, and a positive 1.28%.

3M Company’s highest amplitude of average volatility was 2.91% (last week), 1.50% (last month), and 1.28% (last quarter).

More news about 3M Company.

9. Aspen Group (ASPU) – -5.75%

Aspen Group, Inc., an education technology company, provides online higher education services in the United States. The company offers baccalaureate, master's, and doctoral degree programs in nursing and health sciences, business and technology, arts and sciences, and education fields through Aspen University and United States University. As of April 30, 2022, it had 13,334 degree-seeking students enrolled. Aspen Group, Inc. was founded in 1987 and is based in New York, New York.

NASDAQ ended the session with Aspen Group falling 5.75% to $0.32 on Tuesday while NASDAQ dropped 0.27% to $11,334.27.

Earnings Per Share

As for profitability, Aspen Group has a trailing twelve months EPS of $-0.383.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -28.35%.

More news about Aspen Group.

10. Catalent (CTLT) – -5.7%

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics, and cell and gene therapies in clinical trials. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply services. It serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was incorporated in 2007 and is headquartered in Somerset, New Jersey.

NYSE ended the session with Catalent sliding 5.7% to $49.59 on Tuesday, after five successive sessions in a row of gains. NYSE fell 0.11% to $15,862.29, after two consecutive sessions in a row of gains, on what was a somewhat bearish trend exchanging session today.

Earnings per Share

For profitability, Catalent’s trailing 12 months EPS is $1.8

PE Ratio

The trailing 12 months Catalent price-to-earnings ratio is 27.47. The purchaser of the shares is therefore investing $27.47 per dollar in annual earnings.

For the 12 trailing months, the company’s return-on-equity, which is a measure of the profitability and shareholder equity for a business, was 11.45%.

Annual Top and Bottom Value

At 16:33 EST Catalent stock was valued at $49.59, which is lower than the 52-week high at $115.33 but higher than the low at $40.69.

Revenue Growth

Year-on-year quarterly revenue growth grew by 10.5%, now sitting on 4.83B for the twelve trailing months.

Moving Average

Catalent is worth more than its $50-day moving mean of $46.03 but less than its $200-day moving median of $82.45.

Volume

Today’s last reported volume for Catalent is 2594230 which is 23.35% below its average volume of 3384570.

More news about Catalent.

Stay up to date with our winners and losers daily report